Balyasny Asset Management
CALA

Balyasny Asset Management’s Calithera Biosciences, Inc CALA Stock Holding History

Balyasny Asset Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-919
Closed -$92K – 2162
2018
Q2 		$92K Sell
919
-750
-45% -$85K ﹤0.01% 1713
2018
Q1 		$210K Sell
1,669
-691
-29% -$108K ﹤0.01% 1749
2017
Q4 		$394K Buy
2,360
+1,670
+242% +$428K ﹤0.01% 1638
2017
Q3 		$217K Buy
+690
New +$218K ﹤0.01% 1674
2016
Q2 		– Sell
-530
Closed -$60K – 1532
2016
Q1 		$60K Buy
+530
New +$60.1K ﹤0.01% 1225

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Balyasny Asset Management's CALA Position: Q3 2018 in Review

Balyasny Asset Management sold out of Calithera Biosciences, Inc (CALA) in Q3 2018, closing a stake of 919 shares — an estimated $92K sold.

Balyasny Asset Management first reported a position in CALA in Q1 2016 and held it in 5 quarters. The position peaked at $394K in Q4 2017. 81 funds tracked by Wall St. Rank hold CALA as of Q3 2018.

  • Balyasny Asset Management reported no remaining Calithera Biosciences, Inc position as of Q3 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 919 Calithera Biosciences, Inc shares in Q3 2018, an estimated $92K.
  • Balyasny Asset Management first reported a position in Calithera Biosciences, Inc in Q1 2016 and held it in 5 quarters.
  • Balyasny Asset Management's Calithera Biosciences, Inc position peaked at $394K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.